Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

[Corrigendum] Daily or weekly dosing with EGFR inhibitors, gefitinib and lapatinib, and AKT inhibitor MK2206 in mammary cancer models.

Lubet RA, Steele VE, Juliana MM, Bode A, Moeinpour F, Grubbs CJ.

Oncol Rep. 2019 Jan;41(1):718. doi: 10.3892/or.2018.6802. Epub 2018 Oct 17.

2.

Daily or weekly dosing with EGFR inhibitors, gefitinib and lapatinib, and AKt inhibitor MK2206 in mammary cancer models.

Lubet RA, Steele VE, Juliana MM, Bode A, Moeinpour F, Grubbs CJ.

Oncol Rep. 2018 Sep;40(3):1545-1553. doi: 10.3892/or.2018.6313. Epub 2018 Mar 14. Erratum in: Oncol Rep. 2019 Jan;41(1):718.

PMID:
29565450
3.

Lack of chemopreventive efficacy of metformin in rodent models of urinary bladder, head and neck, and colon/intestine cancer.

Thompson MD, Lubet RA, Mccormick DL, Clapper ML, Bode AM, Juliana MM, Moeinpour F, Grubbs CJ.

Oncol Lett. 2017 Sep;14(3):3480-3486. doi: 10.3892/ol.2017.6632. Epub 2017 Jul 20.

4.

5MeCDDO Blocks Metabolic Activation but not Progression of Breast, Intestine, and Tongue Cancers. Is Antioxidant Response Element a Prevention Target?

Lubet RA, Townsend R, Clapper ML, Juliana MM, Steele VE, McCormick DL, Grubbs CJ.

Cancer Prev Res (Phila). 2016 Jul;9(7):616-23. doi: 10.1158/1940-6207.CAPR-15-0294. Epub 2016 May 5.

5.

Prevention of chemically induced urinary bladder cancers by naproxen: protocols to reduce gastric toxicity in humans do not alter preventive efficacy.

Lubet RA, Scheiman JM, Bode A, White J, Minasian L, Juliana MM, Boring DL, Steele VE, Grubbs CJ.

Cancer Prev Res (Phila). 2015 Apr;8(4):296-302. doi: 10.1158/1940-6207.CAPR-14-0347. Epub 2015 Mar 11.

6.

Lack of effect of metformin on mammary carcinogenesis in nondiabetic rat and mouse models.

Thompson MD, Grubbs CJ, Bode AM, Reid JM, McGovern R, Bernard PS, Stijleman IJ, Green JE, Bennett C, Juliana MM, Moeinpour F, Steele VE, Lubet RA.

Cancer Prev Res (Phila). 2015 Mar;8(3):231-9. doi: 10.1158/1940-6207.CAPR-14-0181-T. Epub 2015 Feb 13.

7.

Osteopontin facilitates ultraviolet B-induced squamous cell carcinoma development.

Chang PL, Hsieh YH, Wang CC, Juliana MM, Tsuruta Y, Timares L, Elmets C, Ho KJ.

J Dermatol Sci. 2014 Aug;75(2):121-32. doi: 10.1016/j.jdermsci.2014.05.002. Epub 2014 May 21.

8.

Effect of intermittent dosing regimens of erlotinib on methylnitrosourea-induced mammary carcinogenesis.

Lubet RA, Szabo E, Iwata KK, Gill SC, Tucker C, Bode A, Steele VE, Juliana MM, Nicastro HL, Grubbs CJ.

Cancer Prev Res (Phila). 2013 May;6(5):448-54. doi: 10.1158/1940-6207.CAPR-12-0322. Epub 2013 Mar 26.

9.

Chemopreventive efficacy of Targretin in rodent models of urinary bladder, colon/intestine, head and neck and mammary cancers.

Lubet RA, Clapper ML, McCormick DL, Pereira MA, Chang WC, Steele VE, Fischer SM, Juliana MM, Grubbs CJ.

Oncol Rep. 2012 May;27(5):1400-6. doi: 10.3892/or.2012.1673. Epub 2012 Feb 3.

PMID:
22307264
10.

Effects of 5,6-benzoflavone, indole-3-carbinol (I3C) and diindolylmethane (DIM) on chemically-induced mammary carcinogenesis: is DIM a substitute for I3C?

Lubet RA, Heckman BM, De Flora SL, Steele VE, Crowell JA, Juliana MM, Grubbs CJ.

Oncol Rep. 2011 Sep;26(3):731-6. doi: 10.3892/or.2011.1316. Epub 2011 May 23.

PMID:
21617870
11.

Efficacy of the EGFr inhibitor Iressa on development of chemically-induced urinary bladder cancers: dose dependency and modulation of biomarkers.

Lubet RA, Lu Y, Bode AM, You M, Verney ZM, Steele VE, Townsend R, Juliana MM, Grubbs CJ.

Oncol Rep. 2011 May;25(5):1389-97. doi: 10.3892/or.2011.1200. Epub 2011 Mar 1.

PMID:
21369704
12.

Screening agents for preventive efficacy in a bladder cancer model: study design, end points, and gefitinib and naproxen efficacy.

Lubet RA, Steele VE, Juliana MM, Grubbs CJ.

J Urol. 2010 Apr;183(4):1598-603. doi: 10.1016/j.juro.2009.12.001. Epub 2010 Feb 20.

PMID:
20172542
13.

Establishment and characterization of an osteopontin-null cutaneous squamous cell carcinoma cell line.

Hsieh YH, Juliana MM, Chang PL.

In Vitro Cell Dev Biol Anim. 2010 Feb;46(2):87-91. doi: 10.1007/s11626-009-9248-8.

14.

Chemopreventive efficacy of naproxen and nitric oxide-naproxen in rodent models of colon, urinary bladder, and mammary cancers.

Steele VE, Rao CV, Zhang Y, Patlolla J, Boring D, Kopelovich L, Juliana MM, Grubbs CJ, Lubet RA.

Cancer Prev Res (Phila). 2009 Nov;2(11):951-6. doi: 10.1158/1940-6207.CAPR-09-0080.

15.

Mycoplasma pulmonis and lymphoma in bioassays in rats.

Schoeb TR, McConnell EE, Juliana MM, Davis JK, Davidson MK, Lindsey JR.

Vet Pathol. 2009 Sep;46(5):952-9. doi: 10.1354/vp.08-VP-0240-S-COM. Epub 2009 May 9.

PMID:
19430000
16.

Lack of efficacy of the statins atorvastatin and lovastatin in rodent mammary carcinogenesis.

Lubet RA, Boring D, Steele VE, Ruppert JM, Juliana MM, Grubbs CJ.

Cancer Prev Res (Phila). 2009 Feb;2(2):161-7. doi: 10.1158/1940-6207.CAPR-08-0134.

17.

Mycoplasma pulmonis and lymphoma.

Schoeb TR, McConnell EE, Juliana MM, Davis JK, Davidson MK, Lindsey JR.

Environ Mol Mutagen. 2009 Jan;50(1):1-3; author reply 6-9. doi: 10.1002/em.20465. No abstract available.

PMID:
19107899
18.

Rosiglitazone, a PPAR gamma agonist: potent promoter of hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancers.

Lubet RA, Fischer SM, Steele VE, Juliana MM, Desmond R, Grubbs CJ.

Int J Cancer. 2008 Nov 15;123(10):2254-9. doi: 10.1002/ijc.23765.

19.

Effect of cranberry juice concentrate on chemically-induced urinary bladder cancers.

Prasain JK, Jones K, Moore R, Barnes S, Leahy M, Roderick R, Juliana MM, Grubbs CJ.

Oncol Rep. 2008 Jun;19(6):1565-70.

20.

Effects of gefitinib (Iressa) on mammary cancers: preventive studies with varied dosages, combinations with vorozole or targretin, and biomarker changes.

Lubet RA, Szabo E, Christov K, Bode AM, Ericson ME, Steele VE, Juliana MM, Grubbs CJ.

Mol Cancer Ther. 2008 Apr;7(4):972-9. doi: 10.1158/1535-7163.MCT-07-2141. Epub 2008 Mar 28.

21.

Short-term modulation of cell proliferation and apoptosis and preventive/therapeutic efficacy of various agents in a mammary cancer model.

Christov K, Grubbs CJ, Shilkaitis A, Juliana MM, Lubet RA.

Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5488-96.

22.

Preventive effects of polyphenon E on urinary bladder and mammary cancers in rats and correlations with serum and urine levels of tea polyphenols.

Lubet RA, Yang CS, Lee MJ, Hara Y, Kapetanovic IM, Crowell JA, Steele VE, Juliana MM, Grubbs CJ.

Mol Cancer Ther. 2007 Jul;6(7):2022-8.

23.

Papilloma development is delayed in osteopontin-null mice: implicating an antiapoptosis role for osteopontin.

Hsieh YH, Juliana MM, Hicks PH, Feng G, Elmets C, Liaw L, Chang PL.

Cancer Res. 2006 Jul 15;66(14):7119-27.

24.

Effects of the farnesyl transferase inhibitor R115777 (Zarnestra) on mammary carcinogenesis: prevention, therapy, and role of HaRas mutations.

Lubet RA, Christov K, You M, Yao R, Steele VE, End DW, Juliana MM, Grubbs CJ.

Mol Cancer Ther. 2006 Apr;5(4):1073-8.

25.

Efficacy of Targretin on methylnitrosourea-induced mammary cancers: prevention and therapy dose-response curves and effects on proliferation and apoptosis.

Lubet RA, Christov K, Nunez NP, Hursting SD, Steele VE, Juliana MM, Eto I, Grubbs CJ.

Carcinogenesis. 2005 Feb;26(2):441-8. Epub 2004 Dec 9.

PMID:
15591091
26.

4-Hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancers in mice: characterization of FHIT and survivin expression and chemopreventive effects of indomethacin.

Lubet RA, Huebner K, Fong LY, Altieri DC, Steele VE, Kopelovich L, Kavanaugh C, Juliana MM, Soong SJ, Grubbs CJ.

Carcinogenesis. 2005 Mar;26(3):571-8. Epub 2004 Dec 9.

PMID:
15591090
27.

Efficacy of 9-cis-retinoic acid and N-(4-hydroxyphenyl) retinamide alone and in combination in mammary cancer prevention.

Cope MB, Steele VE, Lubet RA, Eto I, Juliana MM, Hill DL, Grubbs CJ.

Oncol Rep. 2004 Feb;11(2):465-9.

PMID:
14719085
28.

Prevention of methylnitrosourea-induced mammary cancers by 9-cis-retinoic acid and/or vitamin D3.

Cope MB, Steele VE, Eto I, Juliana MM, Hill DL, Grubbs CJ.

Oncol Rep. 2002 May-Jun;9(3):533-7.

PMID:
11956623
29.

Effects of acute and chronic body weight gain reductions in the evaluation of agents for efficacy in mammary cancer prevention.

Rodríguez-Burford C, Lubet RA, Steele VE, Eto I, Bandy M, Juliana MM, Weiss HL, Grizzle WE, Kelloff GJ, Grubbs CJ.

Oncol Rep. 2001 Mar-Apr;8(2):373-9.

PMID:
11182059
30.

Effect of reduced body weight gain on the evaluation of chemopreventive agents in the methylnitrosourea-induced mammary cancer model.

Rodríguez-Burford C, Lubet RA, Eto I, Juliana MM, Kelloff GJ, Grubbs CJ, Steele VE.

Carcinogenesis. 1999 Jan;20(1):71-6.

PMID:
9934852
31.

Chemopreventive effects of the aromatase inhibitor vorozole (R 83842) in the methylnitrosourea-induced mammary cancer model.

Lubet RA, Steele VE, DeCoster R, Bowden C, You M, Juliana MM, Eto I, Kelloff GJ, Grubbs CJ.

Carcinogenesis. 1998 Aug;19(8):1345-51.

PMID:
9744527
32.

Anhydroretinol, a retinoid active in preventing mammary cancer induced in rats by N-methyl-N-nitrosourea.

Shealy YF, Hill DL, Sani BP, Eto I, Juliana MM, Crubbs CJ.

Oncol Rep. 1998 Jul-Aug;5(4):857-60.

PMID:
9625832
33.

Hormone levels and mammary epithelial cell proliferation in rats treated with a regimen of estradiol and progesterone that mimics the preventive effect of pregnancy against mammary cancer.

Swanson SM, Whitaker LM, Stockard CR, Myers RB, Oelschlager D, Grizzle WE, Juliana MM, Grubbs CJ.

Anticancer Res. 1997 Nov-Dec;17(6D):4639-45.

PMID:
9494582
34.
35.

Chemoprevention of chemically-induced mammary carcinogenesis by indole-3-carbinol.

Grubbs CJ, Steele VE, Casebolt T, Juliana MM, Eto I, Whitaker LM, Dragnev KH, Kelloff GJ, Lubet RL.

Anticancer Res. 1995 May-Jun;15(3):709-16.

PMID:
7645947
36.
37.

Chemoprevention by indomethacin of N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder tumors.

Grubbs CJ, Juliana MM, Eto I, Casebolt T, Whitaker LM, Canfield GJ, Manczak M, Steele VE, Kelloff GJ.

Anticancer Res. 1993 Jan-Feb;13(1):33-6.

PMID:
8476227
38.

Effects of folate deficiency and supplementation on methylnitrosourea-induced rat mammary tumors.

Baggott JE, Vaughn WH, Juliana MM, Eto I, Krumdieck CL, Grubbs CJ.

J Natl Cancer Inst. 1992 Nov 18;84(22):1740-4.

PMID:
1433358
39.

Effect of canthaxanthin on chemically induced mammary carcinogenesis.

Grubbs CJ, Eto I, Juliana MM, Whitaker LM.

Oncology. 1991;48(3):239-45.

PMID:
1902560
40.

Effect of retinyl acetate and 4-hydroxyphenylretinamide on initiation of chemically-induced mammary tumors.

Grubbs CJ, Eto I, Juliana MM, Hardin JM, Whitaker LM.

Anticancer Res. 1990 May-Jun;10(3):661-6.

PMID:
2142393
41.

Effect of miso (Japanese soybean paste) and NaCl on DMBA-induced rat mammary tumors.

Baggott JE, Ha T, Vaughn WH, Juliana MM, Hardin JM, Grubbs CJ.

Nutr Cancer. 1990;14(2):103-9.

PMID:
2120681
42.

Short-term hormone treatment as a chemopreventive method against mammary cancer initiation in rats.

Grubbs CJ, Juliana MM, Whitaker LM.

Anticancer Res. 1988 Jan-Feb;8(1):113-7.

PMID:
3358626
43.

Suppression by pregnancy of chemically induced preneoplastic cells of the rat mammary gland.

Grubbs CJ, Juliana MM, Hill DL, Whitaker LM.

Anticancer Res. 1986 Nov-Dec;6(6):1395-400.

PMID:
3101578
44.
45.

Tumorigenicity of 7,12-dimethylbenz[a]anthracene, its hydroxymethylated derivatives and selected dihydrodiols in the newborn mouse.

Wislocki PG, Juliana MM, MacDonald JS, Chou MW, Yang SK, Lu AY.

Carcinogenesis. 1981;2(6):511-4.

PMID:
6791859
46.

Extradural lymphosarcoma in six cats.

Northington JW, Juliana MM.

J Small Anim Pract. 1978 Jul;19(7):409-16. No abstract available.

PMID:
581208
47.

Polycystic kidney disease in a cat.

Northington JW, Juliana MM.

J Small Anim Pract. 1977 Oct;18(10):663-6. No abstract available.

PMID:
604670

Supplemental Content

Loading ...
Support Center